Cytokines that target immune killer cells against tumors

Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonist

(2020) Giulia Parisi et al.   Nature Communications

Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy

(2020) Meenu Sharma et al.   Nature Communications

De novo design of potent and selective mimics of IL-2 and IL-15

(2019) Daniel-Adriano Silva et al.   NATURE

IL2/anti-IL2 complex combined with CTLA-4, but not PD-1, blockade rescues antitumor NK cell function by regulatory T-cell modulation

(2019) Pamela Caudana et al.   Cancer Immunology Research

Helper T cell differentiation

(2019) Jordy Saravia et al.   Cellular & Molecular Immunology

IL-10-producing regulatory B cells restrain the T follicular helper cell response in primary Sjögren’s syndrome

(2019) Xiang Lin et al.   Cellular & Molecular Immunology

Innate lymphoid cells support regulatory T cells in the intestine through interleukin-2

(2019) Lei Zhou et al.   NATURE

A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors

(2019) Salah-Eddine Bentebibel et al.   Cancer Discovery

Targeting Tumors with IL-10 Prevents Dendritic Cell-Mediated CD8+ T Cell Apoptosis

(2019) Jian Qiao et al.   CANCER CELL

Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial

(2019) Aung Naing et al.   LANCET ONCOLOGY

Effects of interleukin-2 in immunostimulation and immunosuppression

(2019) Jonathan G. Pol et al.   JOURNAL OF EXPERIMENTAL MEDICINE

IL-10-producing T cells and their dual functions

(2019) Tanja Bedke et al.   SEMINARS IN IMMUNOLOGY

Interleukin-15 (dys)regulation of lymphoid homeostasis: Implications for therapy of autoimmunity and cancer

(2019) Thomas A. Waldmann et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

(2018) Julie R. Brahmer et al.   JOURNAL OF CLINICAL ONCOLOGY

Cancer immunotherapy beyond immune checkpoint inhibitors

(2018) Julian A. Marin-Acevedo et al.   Journal of Hematology & Oncology

ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial

(2018) John M Wrangle et al.   LANCET ONCOLOGY

Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery

(2018) Li Tang et al.   NATURE BIOTECHNOLOGY

IL-15 enhanced antibody-dependent cellular cytotoxicity mediated by NK cells and macrophages

(2018) Meili Zhang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Inhibition of Inflammatory Gene Transcription by IL-10 Is Associated with Rapid Suppression of Lipopolysaccharide-Induced Enhancer Activation

(2017) Evan A. Conaway et al.   JOURNAL OF IMMUNOLOGY

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

(2017) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anti-inflammatory effect of IL-10 mediated by metabolic reprogramming of macrophages

(2017) W. K. Eddie Ip et al.   SCIENCE

Targeting IL-10 Family Cytokines for the Treatment of Human Diseases

(2017) Xiaoting Wang et al.   Cold Spring Harbor Perspectives in Biology

Intratumoral CD8 + T-cell Apoptosis Is a Major Component of T-cell Dysfunction and Impedes Antitumor Immunity

(2017) Brendan L. Horton et al.   Cancer Immunology Research

Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma

(2016) Ajjai Alva et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models

(2016) D. H. Charych et al.   CLINICAL CANCER RESEARCH

Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors

(2016) Aung Naing et al.   JOURNAL OF CLINICAL ONCOLOGY

Autocrine Complement Inhibits IL10-Dependent T-cell-Mediated Antitumor Immunity to Promote Tumor Progression

(2016) Y. Wang et al.   Cancer Discovery

Synergistic Innate and Adaptive Immune Response to Combination Immunotherapy with Anti-Tumor Antigen Antibodies and Extended Serum Half-Life IL-2

(2015) Eric F. Zhu et al.   CANCER CELL

The paradoxical role of IL-10 in immunity and cancer

(2015) Mark H. Mannino et al.   CANCER LETTERS

IL10 and PD-1 Cooperate to Limit the Activity of Tumor-Specific CD8+ T Cells

(2015) Z. Sun et al.   CANCER RESEARCH

Macrophage IL-10 Blocks CD8+ T Cell-Dependent Responses to Chemotherapy by Suppressing IL-12 Expression in Intratumoral Dendritic Cells

(2014) Brian Ruffell et al.   CANCER CELL

Preassociation of IL-15 with IL-15R -IgG1-Fc Enhances Its Activity on Proliferation of NK and CD8+/CD44high T Cells and Its Antitumor Action

(2014) S. Dubois et al.   JOURNAL OF IMMUNOLOGY

Antibody-Based Delivery of IL2 and Cytotoxics Eradicates Tumors in Immunocompetent Mice

(2014) K. L. Gutbrodt et al.   MOLECULAR CANCER THERAPEUTICS

The IL-10/STAT3-mediated anti-inflammatory response: recent developments and future challenges

(2013) A. P. Hutchins et al.   Briefings in Functional Genomics

Antibody-Based Delivery of Interleukin-2 to Neovasculature Has Potent Activity Against Acute Myeloid Leukemia

(2013) K. L. Gutbrodt et al.   Science Translational Medicine

PD-1 Blockade Enhances T-cell Migration to Tumors by Elevating IFN-  Inducible Chemokines

(2012) W. Peng et al.   CANCER RESEARCH

IL-10 Directly Activates and Expands Tumor-Resident CD8+ T Cells without De Novo Infiltration from Secondary Lymphoid Organs

(2012) J. Emmerich et al.   CANCER RESEARCH

Regulating the immune system via IL-15 transpresentation

(2012) Eliseo F. Castillo et al.   CYTOKINE

Stability of the recombinant anti-erbB2 scFv-Fc-interleukin-2 fusion protein and its inhibition of HER2-overexpressing tumor cells

(2012) YU-JIA DU et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

PEGylation of interleukin-10 improves the pharmacokinetic profile and enhances the antifibrotic effectivity in CCl4-induced fibrogenesis in mice

(2012) Adriana Mattos et al.   JOURNAL OF CONTROLLED RELEASE

Augmented IL-15R  Expression by CD40 Activation Is Critical in Synergistic CD8 T Cell-Mediated Antitumor Activity of Anti-CD40 Antibody with IL-15 in TRAMP-C2 Tumors in Mice

(2012) M. Zhang et al.   JOURNAL OF IMMUNOLOGY

Exploiting a natural conformational switch to engineer an interleukin-2 ‘superkine’

(2012) Aron M. Levin et al.   NATURE

Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model

(2012) P. Yu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Regulation and Functions of the IL-10 Family of Cytokines in Inflammation and Disease

(2011) Wenjun Ouyang et al.   Annual Review of Immunology

IL-10 Elicits IFNγ-Dependent Tumor Immune Surveillance

(2011) John B. Mumm et al.   CANCER CELL

Dual biological effects of the cytokines interleukin-10 and interferon-γ

(2011) Cailin Moira Wilke et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

A Low-Toxicity IL-2-Based Immunocytokine Retains Antitumor Activity Despite Its High Degree of IL-2 Receptor Selectivity

(2011) S. D. Gillies et al.   CLINICAL CANCER RESEARCH

IL-2 family cytokines: new insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation

(2011) Wei Liao et al.   CURRENT OPINION IN IMMUNOLOGY

Interleukin-15 enhances rituximab-dependent cytotoxicity against chronic lymphocytic leukemia cells and overcomes transforming growth factor beta-mediated immunosuppression

(2011) Esther Moga et al.   EXPERIMENTAL HEMATOLOGY

Interleukin-10 Signaling in Regulatory T Cells Is Required for Suppression of Th17 Cell-Mediated Inflammation

(2011) Ashutosh Chaudhry et al.   IMMUNITY

IL-10 expression by primary tumor cells correlates with melanoma progression from radial to vertical growth phase and development of metastatic competence

(2011) Eijun Itakura et al.   MODERN PATHOLOGY

Modulation of cytokine receptors by IL-2 broadly regulates differentiation into helper T cell lineages

(2011) Wei Liao et al.   NATURE IMMUNOLOGY

Invariant NKT cells modulate the suppressive activity of IL-10-secreting neutrophils differentiated with serum amyloid A

(2010) Carmela De Santo et al.   NATURE IMMUNOLOGY

Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells

(2010) C. Krieg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Interleukin 10 acts on regulatory T cells to maintain expression of the transcription factor Foxp3 and suppressive function in mice with colitis

(2009) Masako Murai et al.   NATURE IMMUNOLOGY

Interleukin-15 combined with an anti-CD40 antibody provides enhanced therapeutic efficacy for murine models of colon cancer

(2009) M. Zhang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Strategies for use of IL-10 or its antagonists in human disease

(2008) Anne O'Garra et al.   IMMUNOLOGICAL REVIEWS

The Biology of Interleukin-2

(2007) Thomas R. Malek   Annual Review of Immunology